Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radionuclides as conditioning before stem cell transplantation.

J G Jurcic1, D A Scheinberg

  • 1Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.

Current Opinion in Hematology
|November 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.

Leukemia·2017
Same author

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.

Leukemia·2017
Same author

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Leukemia·2016
Same author

VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.

Oncogene·2016
Same author

Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.

Cell death & disease·2014
Same author

Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.

Physics in medicine and biology·2011

Targeted radiotherapy with radiolabeled antibodies or bone-seeking agents offers high doses to tumors and bone marrow while sparing normal organs. Further trials are needed to confirm improved outcomes with novel radionuclides and combined radioimmunotherapy-chemotherapy.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiotherapy

Background:

  • Targeted radiotherapy, including radioimmunotherapy and bone-seeking radiopharmaceuticals, aims to deliver high radiation doses to malignant tissues or bone marrow.
  • This approach has the potential to minimize toxicity to surrounding healthy organs.

Purpose of the Study:

  • To review the potential of targeted radiotherapy in delivering high radiation doses.
  • To discuss the encouraging results of high-dose radioimmunotherapy in hematologic malignancies.
  • To explore future directions for improving patient outcomes in targeted radiotherapy.

Main Methods:

  • Review of existing literature on targeted radiotherapy, focusing on radioimmunotherapy and bone-seeking radiopharmaceuticals.
  • Analysis of reported outcomes in lymphoma and leukemia treated with high-dose radioimmunotherapy.

Related Experiment Videos

  • Discussion of potential improvements through alternative radionuclides and combination therapies.

    • Main Results:

    • High-dose radioimmunotherapy has demonstrated encouraging results in treating lymphoma and leukemia.
    • Targeted delivery of radiation can achieve high doses to tumor or bone marrow with reduced normal organ toxicity.

    Conclusions:

    • Targeted radiotherapy offers a promising strategy for cancer treatment by maximizing dose to the target while minimizing side effects.
    • Investigating alternative radionuclides and combining radioimmunotherapy with chemotherapy may enhance therapeutic benefits.
    • Comparative clinical trials are essential to validate the improved efficacy of these advanced targeted radiotherapy approaches.